Custom-designed peptide could treat Alzheimer’s
New findings show a custom-designed peptide has promising potential as a treatment for early Alzheimer’s disease (AD).
The candidate SOBIN-AD, developed by biotechnology company AltPep Corporation, demonstrated potential to improve cognition both before and after the onset of cognitive impairment in pre-clinical trial. SOBIN-AD also reduced Aβ plaque formation and synaptophysin loss in 15-month-old AD mice, the latter being a protein found in neuron cells important for signalling.
The findings follow earlier results presented by AltPep at the Alzheimer’s Association International Conference in July, showing SOBIN-AD uniquely and selectively targets α-sheet toxic oligomers, enhances their clearance in vitro, inhibits plaque formation, and improves cognition in asymptomatic AD mice.
“We are excited to build on the promising preclinical results for our SOBIN-AD therapeutic,” said Valerie Daggett, CEO and Founder of AltPep.
“Our platform, which enables both early detection and treatment, is based on the discovery that toxic oligomers, early triggers for amyloid diseases such as AD, form a nonstandard protein structure called α-sheet. This mechanism is fundamentally different from other Alzheimer’s treatments and could open the door to far more impactful clinical outcomes.”
The full results from AltPep’s pre-clinical trial are being presented at the Clinical Trials on Alzheimer’s Disease Conference (CTAD) in San Diego, California.
Bruno Quinney, Content Team, DDW
